AUS
NZ
UK
CA
USA
IND
Headlnes
- TransMedics reports a 118% revenue increase for Q2 2024, surpassing expectations.
- The company raised its full-year 2024 revenue outlook, indicating significant growth.
- Expansion of logistics services and plans for new clinical programs drive future optimism.
Silviano Trino’s new lungs breathed for 11 hours in TransMedics Group’s (NASDAQ:TMDX) lung machine before they got transplanted into his body. The lungs traveled from the Midwest to Texas and were preserved in TransMedics’ OCS Lung System. The technology was officially approved by the US Food and Drug Administration in March 2018. Trino was one of the first recipients of lungs transplanted using the device. Two weeks after the surgery, he sang in front of his wife, breaking several years of silence. “I’m now doing things I didn’t realize I could do again,” he said.
TransMedics provides technology for lung, heart, and liver transplants. Its lung and heart machines are the only FDA-approved devices in the US for “both standard and expanded criteria donor lungs” and for “extracorporeal perfusion and preservation of donor hearts.”
In May 2019, TransMedics went public with an initial share price of $16 and raised $104.7 million in its IPO. Its share is now trading at around $150 per share, up 100% since the beginning of 2024, while the S&P 500 added 15%.
On July 31, TransMedics, a notable player in healthcare stocks, reported results for the second quarter of 2024. Earnings per share were 35 cents, surpassing the analyst estimate of 21 cents. Revenue of $114.31 million was up by a surprising 118%, exceeding the forecast of $98.97 million. The medical company’s earnings per share have exceeded consensus estimates for four consecutive quarters. TransMedics also raised its full-year 2024 outlook, with revenue guidance of $425 million to $445 million, representing 76% to 84% growth compared to the company's prior year revenue. Its previous guidance was $390 million to $400 million.
The company recently focused on expanding its logistics services through the National OCS Program (NOP). As of June 30, it owned 15 aircraft and purchased two more in July. "We set a new high-water mark for the business in the second quarter of 2024, with product and service revenue growth driven by the sustained momentum of OCS NOP and our transplant logistics network," said CEO Waleed Hassanein, who also revealed plans to launch new OCS lung and heart clinical programs in 2025.
